E-CEL UVEC Cells for Anal Fistula

This trial tests a new treatment called E-CEL UVEC Cells, a type of cell therapy, to determine its effectiveness for people with perianal fistulas. These abnormal tunnels near the anus can cause pain and discomfort. Participants will either receive this new treatment or join a control group without treatment, with the option to switch to the treatment later. Suitable candidates have a single perianal fistula without complications such as abscesses or Crohn's disease and experience minimal pain. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important medical advancements.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are on ongoing systemic steroid treatment or have been treated with steroids in the last 4 weeks before the treatment.

Research has shown that E-CEL UVEC cells have undergone safety testing in humans. Studies using these cells to treat anal fistulas have shown promising results. Patients in past trials generally tolerated the treatment well, with no major safety concerns reported, suggesting the treatment is quite safe. E-CEL UVEC cells originate from human umbilical veins and are specially modified to survive better in the body. This modification has not caused any significant side effects in trials so far. Overall, the safety data appears positive.¹²³⁴⁵

Unlike the standard treatments for anal fistula, which often involve surgical interventions or medications like antibiotics and immunosuppressants, E-CEL UVEC Cells offer a regenerative approach. These cells are derived from umbilical vein endothelial cells and have the potential to promote healing by regenerating tissue and closing fistulas naturally. Researchers are excited because this method could potentially reduce the need for invasive surgery and provide long-term relief, improving the quality of life for patients.

Research has shown that E-CEL UVEC cells might help treat anal fistulas. In this trial, participants in Arm A will receive E-CEL UVEC cells, derived from human umbilical vein cells, which may aid in repairing damaged tissue. Studies have found a healing rate of about 53.8% for similar conditions using stem cell treatments. Early results suggest these cells can support healing. Although data from human trials remain limited, initial findings appear promising for those with anal fistulas. Participants in Arm B will serve as a no-treatment concurrent control and are eligible for crossover.¹²³⁴⁶